Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06121180 · ClinicalTrials.gov registry record · Phase 2

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

A Phase 2 study of Metastatic Uveal Melanoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Recruiting
Registry status
Phase 2
Development phase
32
Enrollment target
4
Study locations

NCT06121180 is a Phase 2 study of Metastatic Uveal Melanoma that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 32 participants, below the 130-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (75% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06121180, a Phase 2 study of Metastatic Uveal Melanoma, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

RECRUITING
Registry status
Phase 2
Development phase
32 participants
Enrollment target
4
Study locations

Study Summary

The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of your body) uveal melanoma. This research study will test the study drugs to see if the combination of Cemiplimab plus Ziv-Aflibercept can make tumors shrink or stop growing.

Conditions Studied

Metastatic Uveal Melanoma

Interventions

  • DRUG Cemiplimab
  • DRUG ZIV-Aflibercept

Study Locations (4)

California

  • The Angeles Clinic and Research Institute - Los Angeles

Florida

  • Moffitt Cancer Center - Tampa

Illinois

  • University of Chicago Medical Center - Chicago

New York

  • Northwell Health Center for Advanced Medicine - New Hyde Park

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2024-11-04
Est. Completion 2030-10-31
Phase Phase 2

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

502 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06121180

The ClinicalTrials.gov registry entry for NCT06121180 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 130-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (75% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Uveal Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.

NCT06121180 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT06121180 about?

NCT06121180 is a clinical study titled "Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma". The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of your body) uveal melanoma. This research study will test the study drugs to see if the combination of Cemiplimab plus Zi...

What is the current status of trial NCT06121180?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2024-11-04. Estimated completion is 2030-10-31.

What conditions does trial NCT06121180 study?

This clinical trial studies the following conditions: Metastatic Uveal Melanoma.

What interventions are being tested in trial NCT06121180?

The interventions under investigation include: Cemiplimab (DRUG), ZIV-Aflibercept (DRUG).

Who is sponsoring clinical trial NCT06121180?

This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06121180 being conducted?

This trial has 4 study locations across California, Florida, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Uveal Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Uveal Melanoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.